LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $58 price target. Zhu, who covers the Healthcare sector, has a strong track record with a 25.9% average return. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $51.91.
LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $58.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Kura Oncology, and IDEAYA Biosciences. According to TipRanks, Zhu has an average return of 25.9% and a 63.60% success rate on recommended stocks.
IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $51.91.